Panther ID:22573: Difference between revisions
Karadolinski (talk | contribs) |
Karadolinski (talk | contribs) |
||
| Line 10: | Line 10: | ||
==== Molecular Function ==== | ==== Molecular Function ==== | ||
Propagation: | |||
1) | |||
The three cervevisiae proteins, PGM1, PGM2, and PGM3, the mouse proteins PGM1 and PGM2, and the fly protein Pgm (last one on the graph) all have experimental annotations to phosphoglucomutase activity. | |||
2) NOT phosphoglucomutase activity to the PGM5 clade. | |||
Up-propagation to AN9, down-propagation to the following Ref Genome species: | |||
Notes: mouse and human had experimental (IDA) annotations to NOT, but based on protein alignments, can extend the propagation because the active sites have been well characterized. Thus, the alignment of active sites makes the NOT vs. the positive annotations clear. See [[Image:GO EUGENE 2009 pipeline1.ppt]] for details. Just a note about one protein that has a wildtype site for one active site but mutated for the others: XENTR_ENSXETG000000001670 is in this clade but has the "active" active site at about residue 675 TASHN (where the NOTs have TASHC or TASHS). But, this protein has the other mutated active sites (~1100 FDAD, while active sites have FDGD, and ~1325 has FDY while active sites have YDY). | |||
Revision as of 16:01, 1 July 2009
HPRT1, hypoxanthine guanine phosphoribosyltransferase
Cross references:
See SourceForge 1893061 and 1893082.
- [PPOD Jaccard1673]: not enough experimental annotations (only human protein UniProtKB:P00492 had exp. ann.) in this subsection of the big PANTHER family, so could not do transfer.
Molecular Function
Propagation:
1) The three cervevisiae proteins, PGM1, PGM2, and PGM3, the mouse proteins PGM1 and PGM2, and the fly protein Pgm (last one on the graph) all have experimental annotations to phosphoglucomutase activity.
2) NOT phosphoglucomutase activity to the PGM5 clade.
Up-propagation to AN9, down-propagation to the following Ref Genome species:
Notes: mouse and human had experimental (IDA) annotations to NOT, but based on protein alignments, can extend the propagation because the active sites have been well characterized. Thus, the alignment of active sites makes the NOT vs. the positive annotations clear. See File:GO EUGENE 2009 pipeline1.ppt for details. Just a note about one protein that has a wildtype site for one active site but mutated for the others: XENTR_ENSXETG000000001670 is in this clade but has the "active" active site at about residue 675 TASHN (where the NOTs have TASHC or TASHS). But, this protein has the other mutated active sites (~1100 FDAD, while active sites have FDGD, and ~1325 has FDY while active sites have YDY).